Home >Deals & Matter Corner>Deal>Actis acquisiton of Rx Propellant

Actis acquisiton of Rx Propellant

JSA has advised Rx Propellant in relation to its acquisition and investment of USD 200 million by Actis, a london-headquartered global investor.

Rx Propellant is a platform operating in the life sciences real estate sector focused in Hyderabad, Bengaluru and Mumbai regions.

Deal Value: USD 200 million.

JSA team comprised Partner – Rajeev Reddy and Senior Associate – Garima Sharma.

POST TAGS

MORE DEALS BY THE AUTHOR

Matter JSA successfully represented Tata Power’s Mundra Plant (4150 MW) before Central Electricity Regulatory Commission (CERC) qua grant of capital cost on account of installation of Flue Gas Desulphurisation (FGD)
Deal JSA represents Grasim Industries Limited’s Birla Paints Division before the CCI to secure a Section 26(1) investigation order against Asian Paints Limited for alleged abuse of dominance
Matter UltraTech Cement Limited Secures Regulatory Clarity for Hybrid Wind-Solar Connectivity with JSA’s
 

Search

Popular Posts

Deals & Matter Corner

  • Matter
  • July 2, 2025

JSA successfully represented Tata Power’s Mundra Plant (4150 MW) before Central Electricity Regulatory Commission (CERC) qua grant of capital cost on account of installation of Flue Gas Desulphurisation (FGD)
  • Deal
  • July 2, 2025

JSA represents Grasim Industries Limited’s Birla Paints Division before the CCI to secure a Section 26(1) investigation order against Asian Paints Limited for alleged abuse of dominance
  • Matter
  • July 1, 2025

UltraTech Cement Limited Secures Regulatory Clarity for Hybrid Wind-Solar Connectivity with JSA’s
  • Deal
  • June 30, 2025

JSA acts as legal counsel to IndiGrid in the acquisition of assets from ReNew, for INR 2,100 Crores
  • Deal
  • June 28, 2025

CCI approves Alpha Wave Global’s and International Holding Company’s investment in Haldiram Snacks Food Private Limited
  • Deal
  • June 24, 2025

Initial Public Offering of Oswal Pumps Limited
View More